The DOI matches its OpenAlex record; 35 of the 35 references it cites were found in a registry or an index.
Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo
Open accessAbstract
Paclitaxel concentrations in the brain are very low after intravenous injection. Since paclitaxel is excluded from some tumors by p-glycoprotein (p-gp), the same mechanism may prevent entry into the brain. In vitro, paclitaxel transport was examined in capillaries from rat brains by confocal microscopy using BODIPY Fl-paclitaxel. Western blots and immunostaining demonstrated apical expression of p-gp in isolated endothelial cells, vessels, and tissue. Secretion of BODIPY Fl-paclitaxel into capillary lumens was specific and energy-dependent. Steady state luminal fluorescence significantly exceeded cellular fluorescence and was reduced by NaCN, paclitaxel, and SDZ PSC-833 (valspodar), a p-gp blocker. Leukotriene C(4) (LTC(4)), an Mrp2-substrate, had no effect. Luminal accumulation of NBDL-cyclosporin, a p-gp substrate, was inhibited by paclitaxel. In vivo, paclitaxel levels in the brain, liver, kidney, and plasma of nude mice were determined after intravenous injection. Co-administration of valspodar led to increased paclitaxel levels in brains compared to monotherapy. Therapeutic relevance was proven for nude mice with implanted intracerebral human U-118 MG glioblastoma. Whereas paclitaxel did not affect tumor volume, co-administration of paclitaxel (intravenous) and PSC833 (peroral) reduced tumor volume by 90%. Thus, p-gp is an important obstacle preventing paclitaxel entry into the brain, and inhibition of this transporter allows the drug to reach sensitive tumors within the CNS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Schinkel, A. H., Smit, J. J. M., van Tellingen, O., Beijnen, J. H., Wagenaar, E., van Deemter, L., Mol, C. A. A. M., van der Valk, M. A., Robanus-Maandag, E. C., te Riele, H. P. J., et al. (1994) · Cell · doi:10.1016/0092-8674(94)90212-7 · Cited by 2,281
Sparreboom, A., van Asperen, J., Mayer, U., Schinkel, A. H., Smit, J. W., Meijer, D. K. F., Borst, P., Nooijen, W. J., Beijnen, J. H., & van Tellingen, O. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.5.2031 · Cited by 882
Brodie, S. E. (1996) · Survey of Ophthalmology · doi:10.1016/s0039-6257(96)80075-0 · Cited by 745
Muggia, F. M., Braly, P. S., Brady, M. F., Sutton, G., Niemann, T. H., Lentz, S. L., Alvarez, R. D., Kucera, P. R., & Small, J. M. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.1.106 · Cited by 601
Communication between Multiple Drug Binding Sites on P-glycoprotein
Martin, C., Berridge, G., Higgins, C. F., Mistry, P., Charlton, P., & Callaghan, R. (2000) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)12429-7 · Cited by 418
Xenobiotic Transport across Isolated Brain Microvessels Studied by Confocal Microscopy
Miller, D. S., Nobmann, S. N., Gutmann, H., Toeroek, M., Drewe, J., & Fricker, G. (2000) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)12708-3 · Cited by 307
Self-citationMolecular and Cellular Biology of Multidrug Resistance in Tumor Cells
(1991) · Springer eBooks · doi:10.1007/978-1-4615-3794-6 · Cited by 276
Mayer, U., Wagenaar, E., Dorobek, B., Beijnen, J. H., Borst, P., & Schinkel, A. H. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119784 · Cited by 269
BEAULIEU, É., DEMEULE, M., GHITESCU, L., & BÉLIVEAU, R. (1997) · Biochemical Journal · doi:10.1042/bj3260539 · Cited by 253
Audus, K. L., & Borchardt, R. T. (1986) · Pharmaceutical Research · doi:10.1023/a:1016337202335 · Cited by 247
Cited by
Drug resistance in brain diseases and the role of drug efflux transporters
Löscher, W., & Potschka, H. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1728 · Cited by 900
Blood-brain barrier active efflux transporters: ATP-binding cassette gene family
Löscher, W., & Potschka, H. (2005) · NeuroRX · doi:10.1602/neurorx.2.1.86 · Cited by 872
The Blood-Brain Barrier and Cancer: Transporters, Treatment, and Trojan Horses
Deeken, J. F., & Löscher, W. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2854 · Cited by 721
Lockman, P. R., Mittapalli, R. K., Taskar, K. S., Rudraraju, V., Gril, B., Bohn, K. A., Adkins, C. E., Roberts, A., Thorsheim, H. R., Gaasch, J. A., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1564 · Cited by 693
Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases
Löscher, W., & Potschka, H. (2005) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2005.04.006 · Cited by 617
Paclitaxel: a review of adverse toxicities and novel delivery strategies
Marupudi, N. I., Han, J. E., Li, K. W., Renard, V. M., Tyler, B. M., & Brem, H. (2007) · Expert Opinion on Drug Safety · doi:10.1517/14740338.6.5.609 · Cited by 510
Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies
Brunden, K. R., Trojanowski, J. Q., & Lee, V. M.-Y. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2959 · Cited by 440
Systemic administration of epothilone B promotes axon regeneration after spinal cord injury
Ruschel, J., Hellal, F., Flynn, K. C., Dupraz, S., Elliott, D. A., Tedeschi, A., Bates, M., Sliwinski, C., Brook, G., Dobrindt, K., et al. (2015) · Science · doi:10.1126/science.aaa2958 · Cited by 432
Chemotherapy Delivery Issues in Central Nervous System Malignancy: A Reality Check
Muldoon, L. L., Soussain, C., Jahnke, K., Johanson, C., Siegal, T., Smith, Q. R., Hall, W. A., Hynynen, K., Senter, P. D., Peereboom, D. M., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.9861 · Cited by 417
Zhang, B., Carroll, J., Trojanowski, J. Q., Yao, Y., Iba, M., Potuzak, J. S., Hogan, A.-M. L., Xie, S. X., Ballatore, C., Smith, A. B., et al. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.4922-11.2012 · Cited by 401
“The results obtained with EpoD also provide impetus to identify additional BBB-permeable MT-stabilizing agents that might have an even greater therapeutic index.”
BackgroundInfluentialMiller, D. S., Bauer, B., & Hartz, A. M. S. (2008) · Pharmacological Reviews · doi:10.1124/pr.107.07109 · Cited by 392
Self-citationNatural Products/Bioactive Compounds as a Source of Anticancer Drugs
Asma, S. T., Acaroz, U., Imre, K., Morar, A., Shah, S. R. A., Hussain, S. Z., Arslan-Acaroz, D., Demirbas, H., Hajrulai-Musliu, Z., Istanbullugil, F. R., et al. (2022) · Cancers · doi:10.3390/cancers14246203 · Cited by 378
Régina, A., Demeule, M., Ché, C., Lavallée, I., Poirier, J., Gabathuler, R., Béliveau, R., & Castaigne, J. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.260 · Cited by 368
Regulation of P-glycoprotein and other ABC drug transporters at the blood–brain barrier
Miller, D. S. (2010) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2010.03.003 · Cited by 361
Self-citationElectrospun Micro- and Nanofibers for Sustained Delivery of Paclitaxel to Treat C6 Glioma in Vitro
Xie, J., & Wang, C.-H. (2006) · Pharmaceutical Research · doi:10.1007/s11095-006-9036-z · Cited by 339
Breedveld, P., Beijnen, J. H., & Schellens, J. H. M. (2006) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2005.11.009 · Cited by 323
Brunden, K. R., Zhang, B., Carroll, J., Yao, Y., Potuzak, J. S., Hogan, A.-M. L., Iba, M., James, M. J., Xie, S. X., Ballatore, C., et al. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.3059-10.2010 · Cited by 320
Hartz, A. M. S., Miller, D. S., & Bauer, B. (2010) · Molecular Pharmacology · doi:10.1124/mol.109.061754 · Cited by 318
Self-citationZhu, Q., Ling, X., Yang, Y., Zhang, J., Li, Q., Niu, X., Hu, G., Chen, B., Li, H., Wang, Y., et al. (2019) · Advanced Science · doi:10.1002/advs.201801899 · Cited by 304
Paclitaxel nanoparticles for the potential treatment of brain tumors
Koziara, J. M., Lockman, P. R., Allen, D. D., & Mumper, R. J. (2004) · Journal of Controlled Release · doi:10.1016/j.jconrel.2004.07.006 · Cited by 299
Bauer, B., Hartz, A. M. S., Fricker, G., & Miller, D. S. (2004) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)05623-2 · Cited by 294
Self-citationMarchetti, S., Mazzanti, R., Beijnen, J. H., & Schellens, J. H. M. (2007) · The Oncologist · doi:10.1634/theoncologist.12-8-927 · Cited by 284
Delivery of peptide and protein drugs over the blood–brain barrier
Brasnjevic, I., Steinbusch, H. W. M., Schmitz, C., & Martinez-Martinez, P. (2009) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2008.12.002 · Cited by 279
Bauer, B., Hartz, A. M. S., & Miller, D. S. (2007) · Molecular Pharmacology · doi:10.1124/mol.106.029512 · Cited by 275
Self-citationBreast Cancer Resistance Protein and P-Glycoprotein in Brain Cancer: Two Gatekeepers Team Up
Agarwal, S., M.S. Hartz, A., F. Elmquist, W., & Bauer, B. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211797440186 · Cited by 272
Self-citationHartz, A. M. S., Bauer, B., Block, M. L., Hong, J.-S., & Miller, D. S. (2008) · The FASEB Journal · doi:10.1096/fj.08-106997 · Cited by 268
Self-citationPhase I Study of GRN1005 in Recurrent Malignant Glioma
Drappatz, J., Brenner, A., Wong, E. T., Eichler, A., Schiff, D., Groves, M. D., Mikkelsen, T., Rosenfeld, S., Sarantopoulos, J., Meyers, C. A., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2481 · Cited by 190
Kurzrock, R., Gabrail, N., Chandhasin, C., Moulder, S., Smith, C., Brenner, A., Sankhala, K., Mita, A., Elian, K., Bouchard, D., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0566 · Cited by 168
Developing therapeutic approaches to tau, selected kinases, and related neuronal protein targets
Lee, V. M.-Y., Brunden, K. R., Hutton, M., & Trojanowski, J. Q. (2011) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006437 · Cited by 122
“The taxanes, including paclitaxel and docetaxel, have poor BBB permeability that is thought to result, at least in part, from these molecules being substrates for the P-glycoprotein (Pgp) transporter that prevents xenobiotics from accumulating in the brain (Sparreboom et al. 1997; Fellner et al. 2002).”
BackgroundEnhancing autophagy in Alzheimer's disease through drug repositioning
Eshraghi, M., Ahmadi, M., Afshar, S., Lorzadeh, S., Adlimoghaddam, A., Rezvani Jalal, N., West, R., Dastghaib, S., Igder, S., Torshizi, S. R. N., et al. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108171 · Cited by 89
Application of nanoparticles on diagnosis and therapy in gliomas.
Hernández-Pedro, N. Y., Rangel-López, E., Magaña-Maldonado, R., de la Cruz, V. P., Santamaría del Angel, A., Pineda, B., & Sotelo, J. (2013) · BioMed Research International · doi:10.1155/2013/351031 · Cited by 84
Establishment of a Human iPSC- and Nanofiber-Based Microphysiological Blood–Brain Barrier System
Qi, D., Wu, S., Lin, H., Kuss, M. A., Lei, Y., Krasnoslobodtsev, A., Ahmed, S., Zhang, C., Kim, H. J., Jiang, P., et al. (2018) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.8b03962 · Cited by 62
Mechanistic Insights for Drug Repurposing and the Design of Hybrid Drugs for Alzheimer’s Disease
Padhi, D., & Govindaraju, T. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00335 · Cited by 47
Epothilone D inhibits microglia-mediated spread of alpha-synuclein aggregates
Valdinocci, D., Grant, G. D., Dickson, T. C., & Pountney, D. L. (2018) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2018.04.006 · Cited by 20
Competition for microtubule lattice spacing between a microtubule expander and compactor
Paquette, A. L., Tetlalmatzi, S. C., Haineault, J. A. G., Li, Y., Finkel, N., Hendricks, A. G., Brouhard, G. J., & Sébastien, M. (2025) · Current Biology · doi:10.1016/j.cub.2025.07.080 · Cited by 17
Metadata
- Authors
- Fellner, S., Bauer, B., Miller, D. S., Schaffrik, M., Fankhänel, M., Spruß, T., Bernhardt, G., Graeff, C., Färber, L., Gschaidmeier, H., Buschauer, A., & Fricker, G.
- Venue
- Journal of Clinical Investigation
- Publisher
- American Society for Clinical Investigation
- Published
- 2002-11-01
- Volume
- 110
- Issue
- 9
- Pages
- 1309-1318
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2162592548
- Cited by
- 359
- References
- 35
- FWCI
- 5.90
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.